サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：女性用尿失禁治療デバイスの世界市場-2022-2029
市場調査レポート
商品コード
1140744

女性用尿失禁治療デバイスの世界市場-2022-2029

Global Female Urinary Incontinence Treatment Device Market - 2022-2029
出版日: | 発行: DataM Intelligence | ページ情報: 英文 170 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
女性用尿失禁治療デバイスの世界市場-2022-2029
出版日: 2022年10月20日
発行: DataM Intelligence
ページ情報: 英文 170 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

市場力学

妊婦における尿失禁の有病率の上昇

2022年1月にBMCが発表した調査によると、1243人の女性が登録されました。妊娠中の尿失禁の有病率は52.0％でした。ほとんどの女性が軽度または中等度の尿失禁に苦しんでいます。多重ロジスティック回帰により、5つの危険因子が同定されました。妊娠前の尿失禁が最も強い予測因子であり、次いで経膣分娩歴、コーヒー摂取、小児期の尿崩症、尿路感染症の既往が挙げられました。尿失禁は、妊娠中の健康関連QOLに大きな影響を及ぼしていました。排尿症状について専門家の助けを求めた妊婦は、わずか14.8％でした。尿失禁と有意に関連する要因は、年齢層、妊娠期間、分娩数、尿失禁の既往、便秘、最終分娩様式、尿路感染症の既往、妊娠中の肥満度などでした。

さらに、より低価格のプライベートブランド商品の普及が、予測期間中の市場成長を後押ししています。女性のストレス性尿失禁治療器市場にはさまざまな製品が存在するため、小規模なプレーヤーが関心を集め、低価格で製品を販売しています。プライベートブランドが大幅に低価格で浸透することで、女性用尿失禁ストレス治療器の平均的な全体価格が低下することが予想されます。高価な製品への需要が阻害される可能性が高いため、女性用ストレス性尿失禁治療器の世界市場の成長を抑制する可能性があります。

地理的浸透度。

予測期間中、北米が支配的な地域となっています。

本調査では地域別に、北米、欧州、アジア太平洋、南米、中東・アフリカなど、世界市場における女性用尿失禁治療デバイス市場を分析しています。

2021年の女性用尿失禁治療デバイスの世界市場では、北米が圧倒的な地位を占めています。北米では、米国が予測期間中にかなりの成長を表すと予想されます。米国では、妊婦の尿失禁や糖尿病によるストレス性尿失禁、婦人科疾患、閉経後の女性の尿失禁の有病率が上昇していることから、女性用尿失禁治療デバイスは潜在的な成長が期待されます。

アジア太平洋地域の市場は、認知度の向上、手頃な価格で最適な施設を提供するための医療への投資の増加、社会経済の発展などにより、予測期間中に大きく拡大すると予想されています。中国では、喫煙する女性の数が増加していることから、市場の拡大が見込まれています。新興国における有力企業による投資の増加が市場を押し上げると予想されます。中東・アフリカ市場は、認知度の低さ、可処分所得の低さ、医療施設の制限により、緩やかに拡大すると予測されます。

競合情勢

世界市場の成長に貢献している女性用尿失禁治療デバイス市場の主要プレイヤーは、Karl Storz、Johnson &Johnson、Coloplast、Boston Scientific、Teleflex、American Medical Solutionsなどです。大手企業は、女性用尿失禁治療デバイス市場の世界の成長のために、新製品の投入や拡大戦略を採用しています。2022年5月、女性主導の企業であるレノビアは、女性の骨盤底障害に対するデジタル治療薬の開発を進め、レバ処方者1000人による女性尿失禁の第一選択治療へのアクセスを実現します。Levaは、過活動膀胱を含む尿失禁（UI）の症状を軽減する、使いやすい骨盤内健康管理システムです。Levaが医療従事者の間で急速に普及しているのは、UIに対する保存的治療へのアクセスを改善したいという医療従事者の意向を反映したものです。この症状は、米国の成人女性の62％が罹患しており、時間の経過とともに進行・悪化する傾向があります。2021年12月、カルデラ・メディカルは、ストレス性尿失禁のための新デサラTVezのFDA承認を発表しました。同社は、ストレス性尿失禁に悩む女性のための治療オプションの製品ポートフォリオを拡大します。カルデラ・メディカルは、数十人の大手外科医と協力し、使いやすさと患者の安全性を強化したデサラTVezを世に送り出しました。2022年2月、クックの医療事業はクーパー・カンパニーズに買収され、MedSurg部門内のクックのリプロダクティブヘルス事業全体を販売することになりました。クーパー・カンパニーズは、女性の健康と生殖に関するソリューションに焦点を当て、ARTの旅のすべてのステップに革新的な製品とサービスを提供しています。一部の主要プレイヤーは、事業拡大のために合併・提携戦略に従っています。例えば、2020年10月、ジョンソン・エンド・ジョンソンは、約65億米ドルでモメンタ・ファーマシューティカルズ社の買収を完了しました。モメンタは、希少疾患向け医薬品の開発で素晴らしい成果を上げています。共に事業を拡大します。

COVID-19の影響世界の女性用尿失禁治療デバイス市場にネガティブな影響を与えます。

COVID-19の発生は、世界の女性用尿失禁治療デバイス市場の成長にマイナスの影響を及ぼしています。病院サービスの制限により、尿失禁患者の専門的な調査や外科的な管理に影響が出ています。したがって、COVID-19の大流行は、2020年の女性用尿失禁治療デバイスの市場価値にマイナスの影響を及ぼしました。

世界の女性用尿失禁治療装置市場レポートでは、約61の市場データ表、50の図、170ページの構成で提供しています

目次

第1章 調査手法と調査範囲

  • 調査手法
  • 調査目的および調査範囲

第2章 市場の定義と概要

第3章 エグゼクティブサマリー

  • 製品タイプ別市場内訳
  • 使用材料別市場内訳
  • エンドユーザー別市場内訳
  • 地域別市場内訳

第4章 市場力学

  • 市場影響要因
    • 促進要因
      • 妊娠中の女性における尿失禁の有病率の上昇
      • 糖尿病、婦人科疾患、閉経後女性の尿失禁など別ストレス性尿失禁の増加
      • 子宮摘出手術の増加
      • 女性における肥満の増加
    • 抑制要因
      • 尿失禁治療に対する女性の認識不足
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • バリューチェーン分析
  • PEST分析
  • プライシング分析
  • 法規制分析
  • 保険償還分析
  • アンメットニーズ
  • 特許動向

第6章 COVID-19の分析

  • COVID-19の市場分析
    • COVID-19以前の市場シナリオ
    • COVID-19の現在の市場シナリオ
    • COVID-19の後、あるいは将来のシナリオ
  • COVID-19の中での価格ダイナミクス
  • 需要-供給スペクトラム
  • パンデミック時の市場に関連する政府の取り組み
  • メーカーの戦略的な取り組み
  • まとめ

第7章 製品タイプ別

  • 尿道デバイス
  • 膣内留置器

第8章 使用材料別

  • 発泡ポリウレタン
  • シリコーン

第9章 エンドユーザー別

  • 病院
  • 専門クリニック
  • 外来手術センター

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他の南米地域
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ地域

第11章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A（合併・買収）分析

第12章 企業プロファイル

  • Bard Medical
    • 企業概要
    • 製品ポートフォリオと説明
    • 主なハイライト
    • 財務概要
  • Karl Storz
  • Johnson & Johnson
  • Coloplast
  • Boston Scientific
  • Teleflex
  • AMERICAN MEDICAL SOLUTIONS
  • Ethicon, Inc.
  • Caldera Medical Inc
  • COOK MEDICAL（*LIST NOT EXHAUSTIVE*）

第13章 重要考察

第14章 DataM

目次
Product Code: DMMD3131

Market Overview

Female Urinary Incontinence Treatment Device Market was valued at USD YY million in 2021. It is forecasted to reach USD YY million by 2029, growing at a CAGR of YY % during the forecast period (2022-2029).

Female urinary incontinence has been diagnosed as a condition that causes involuntary urination. Urinary incontinence or stress urinary incontinence typically occurs during physical activities, such as sneezing, coughing, running, or even during weightlifting, as these activities exert pressure on the urinary bladder. Urinary urge and stress incontinence are different, as the former occurs when the bladder muscles are contracted. Urinary stress incontinence affects women more than men and is mostly due to weak muscle sphincter, which can lead to social isolation. Female urinary incontinence is of two types: the first is urethral hypermobility and the second is due to an inherent sphincter deficiency. In the case of urethra hypermobility, increased abdominal pressure changes the position of the urethra. On the other hand, in the inherent sphincter of the deficiency, the sphincter has lost its ability to seal the deficiency of the intestinal sphincter. The major factors propelling the growth of the female urinary incontinence treatment device market are the rising prevalence of urinary incontinence in pregnant women, stress urinary incontinence due to diabetes, gynecology disorders, and urinary incontinence in postmenopausal women and rising cases of hysterectomy. Moreover, the rising incidence of obesity in the female population is the major factor expected to deliver significant growth to the market in the upcoming period.

Market Dynamics: Rising prevalence of urinary incontinence in pregnant women

According to the research published by BMC in January 2022, 1243 women were enrolled in the study. The prevalence of urinary incontinence during pregnancy was 52.0%. Most women suffer from mild or moderate incontinence. Multiple logistic regressions identified five risk factors. Urinary incontinence before pregnancy was the strongest predictor of incontinence, followed by the history of vaginal birth, coffee consumption, childhood enuresis and history of urinary tract infection. Urinary incontinence had a significant impact on health-related quality of life during pregnancy. Only 14.8% of pregnant women sought professional help for urinary symptoms. Factors significantly associated with urinary incontinence included age group, gestational age, parity, prior urinary incontinence, constipation, last childbirth mode of delivery, previous urinary tract infection, and body mass index during pregnancy.

Moreover, an increase in the penetration of private-label brands at much lower prices drives market growth in the forecast period. Due to the presence of a wide range of products on the market for female stress urinary incontinence treatment devices, small players are gaining interest and selling their products at lower prices. An increase in the penetration of private-label brands at much lower prices is expected to reduce the average overall price of female urinary incontinence stress treatment devices. It is likely to constrain the growth of the global market for female stress urinary incontinence treatment devices, as it is likely to hinder demand for expensive products.

Market Segmentation: The internal vaginal device segment is projected to be the dominant segment in the market during the forecast period.

Based on the product type, the female urinary incontinence treatment device market has been classified into urethral devices and internal vaginal devices.

The internal vaginal devices segment can be further categorized into traditional devices and custom-made devices. Urinary stress incontinence is significantly more common in women than in men. Female urinary incontinence treatment device occurs when pelvic floor muscles or urinary sphincter are likely to lose strength, either due to women's childbirth or men's prostate surgery. Thus, due to such factors, the internal vaginal device is expected to hold a dominant position in the market.

The female urinary incontinence treatment device is segmented based on end-user, which includes hospitals, speciality clinics, and ambulatory surgical centers.

The hospital pharmacies segment is expected to hold a significant market share in the female urinary incontinence treatment device market. Hospital in the end-user segment is expected to have a significant share of the global market for urinary incontinence devices due to the large patient population treated in hospitals suffering from urinary incontinence. Moreover, hospitals are expected to grow with the highest CAGR in the forthcoming period with the rise in technological advancement in the industry.

Furthermore, the female urinary incontinence treatment device is segmented on the basis of material used, which includes polyurethane foam and silicone. Polyurethane foam is the dominating segment along with projected to grow with the highest CAGR in the forthcoming period.

Geographical Penetration: North America is the dominating region during the forecast period.

Based on geography, the study analyzes the female urinary incontinence treatment device market in the global market, including North America, Europe, Asia-Pacific, South America, and the Middle East & Africa.

North America is holding a dominant position in the global female urinary incontinence treatment device market in 2021. In North America, the U.S. is expected to represent considerable growth during the forecast period. In the U.S., the female urinary incontinence treatment device is expected to have potential growth due to the rising prevalence of urinary incontinence in pregnant women and stress urinary incontinence due to diabetes, gynecology disorders, and urinary incontinence in postmenopausal women.

The Asia-Pacific market is projected to expand significantly during the forecast period due to increased awareness, increased investment in health care to provide optimum facilities at affordable cost, and socio-economic development. The increase in the number of women smoking in China is expected to boost the market. Increased investment by prominent players in developing countries is expected to boost the market. The Middle East & Africa market is projected to expand slowly due to a lack of awareness, low disposable income, and limited healthcare facilities.

Competitive Landscape:

The key female urinary incontinence treatment device market players contributing to the global market's growth include Karl Storz, Johnson & Johnson, Coloplast, Boston Scientific, Teleflex, and American Medical Solutions, among others. The major players are adopting new product launches and expansion strategies for global growth in the female urinary incontinence treatment device market. In May 2022, Renovia, a women-led company, advances the development of digital therapeutics for female pelvic floor disorders access to first-line treatment for female urinary incontinence with 1,000 leva prescribers. Leva is a pelvic health system that is easy to use and that help woman decreases the symptoms of urinary incontinence (UI) symptoms, including overactive bladder. Leva's accelerated adoption among healthcare providers reflects their desire to improve access to conservative treatment for UI. This condition affects 62% of adult women in the U.S. and tends to progress and worsen over time. In December 2021, Caldera Medical announced FDA approval for the New Desara TVez for Stress Urinary Incontinence. The company expands its product portfolio of treatment options for women suffering from Stress Urinary Incontinence. Caldera Medical collaborated with dozens of leading surgeons to bring enhanced ease of use and patient safety to life in the form of Desara TVez. In February 2022, Cook's medical business was acquired by CooperCompanies to sell the entirety of Cook's Reproductive Health business within the MedSurg division. Cooper Companies focuses on women's health and fertility solutions, providing innovative products and services for every step in the ART journey. Some key players follow merger and collaboration strategies to expand their business. For instance, in October 2020, Johnson & Johnson completed the acquisition of Momenta Pharmaceuticals, Inc. for approximately $6.5 billion. Momenta has made excellent progress in developing its medicines for rare diseases. Together they expand their business.

COVID-19 Impact: Negative impact on the global female urinary incontinence treatment device market.

The outbreak of COVID-19 has negatively impacted the growth of the female urinary incontinence treatment device market globally. Restrictions on hospital services have affected the specialized investigation and surgical management of patients with urinary incontinence. Therefore, the COVID-19 pandemic had a negative impact on the market value of the female urinary incontinence treatment device market in 2020.

The global female urinary incontinence treatment device market report would provide an access to approximately 61 market data tables, 50 figures and 170 pages

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

  • 3.1. Market Snippet by Product Type
  • 3.2. Market Snippet by Material used
  • 3.3. Market Snippet by End-user
  • 3.4. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rising prevalence of urinary incontinence in pregnant women
      • 4.1.1.2. Stress urinary incontinence due to diabetes, gynecology disorders, and urinary incontinence in postmenopausal women
      • 4.1.1.3. Rising cases of hysterectomy
      • 4.1.1.4. Rising incidence of obesity in the female population
    • 4.1.2. Restraint
      • 4.1.2.1. Lack of awareness among women regarding urinary incontinence treatment
    • 4.1.3. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Value Chain Analysis
  • 5.4. PEST Analysis
  • 5.5. Pricing Analysis
  • 5.6. Regulatory Analysis
  • 5.7. Reimbursement Analysis
  • 5.8. Unmet Needs
  • 5.9. Patent Trends

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Product Type

  • 7.1. Introduction
  • 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type Segment
  • 7.3. Market Attractiveness Index, By Product Type Segment
    • 7.3.1. Urethral devices
      • 7.3.1.1. Introduction
      • 7.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 7.3.2. Internal vaginal devices

8. By Material used

  • 8.1. Introduction
  • 8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Material used Segment
  • 8.3. Market Attractiveness Index, By Material Segment
    • 8.3.1. Polyurethane Foam
      • 8.3.1.1. Introduction
      • 8.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 8.3.2. Silicone

9. By End user

  • 9.1. Introduction
  • 9.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user Segment
  • 9.3. Market Attractiveness Index, By End user Segment
    • 9.3.1. Hospitals
      • 9.3.1.1. Introduction
      • 9.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 9.3.2. Specialty clinics
    • 9.3.3. Ambulatory surgical centers

10. By Region

  • 10.1. Introduction
  • 10.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
  • 10.3. Market Attractiveness Index, By Region
  • 10.4. North America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Material used
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. U.S.
      • 10.4.6.2. Canada
      • 10.4.6.3. Mexico
  • 10.5. Europe
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Material used
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. Germany
      • 10.5.6.2. U.K.
      • 10.5.6.3. France
      • 10.5.6.4. Italy
      • 10.5.6.5. Spain
      • 10.5.6.6. Rest of Europe
  • 10.6. South America
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Material used
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 10.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.6.6.1. Brazil
      • 10.6.6.2. Argentina
      • 10.6.6.3. Rest of South America
  • 10.7. Asia Pacific
    • 10.7.1. Introduction
    • 10.7.2. Key Region-Specific Dynamics
    • 10.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Material used
    • 10.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 10.7.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.7.6.1. China
      • 10.7.6.2. India
      • 10.7.6.3. Japan
      • 10.7.6.4. Australia
      • 10.7.6.5. Rest of Asia Pacific
  • 10.8. Middle East and Africa
    • 10.8.1. Introduction
    • 10.8.2. Key Region-Specific Dynamics
    • 10.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Material used
    • 10.8.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 10.8.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Bard Medical*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Karl Storz
  • 12.3. Johnson & Johnson
  • 12.4. Coloplast
  • 12.5. Boston Scientific
  • 12.6. Teleflex
  • 12.7. AMERICAN MEDICAL SOLUTIONS
  • 12.8. Ethicon, Inc.
  • 12.9. Caldera Medical Inc
  • 12.10. COOK MEDICAL (*LIST NOT EXHAUSTIVE*)

13. Premium Insights

14. DataM Intelligence Analysis

  • 14.1. Appendix
  • 14.2. About Us and Services
  • 14.3. Contact Us